切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2021, Vol. 09 ›› Issue (04) : 407 -414. doi: 10.3877/cma.j.issn.2095-5782.2021.04.011

基础研究

基于c-Met抗体的近红外荧光探针用于肝癌的活体成像研究
易柳彤1, 杨美林2, 宫娜娜3, 余美红1, 曹婉维1, 李展宇1,†(), 李丹2   
  1. 1. 519000　广东珠海，中山大学附属第五医院病理科
    2. 519000　广东珠海，中山大学附属第五医院广东省生物医学影像重点实验室；519000　广东珠海，中山大学附属第五医院广东省分子影像技术工程研究中心
    3. 519000　广东珠海，中山大学附属第五医院检验科
  • 收稿日期:2021-09-18 出版日期:2021-11-25
  • 通信作者: 李展宇
  • 基金资助:
    中山大学附属第五医院"五个五"工程青年人才项目(2016972024656)

c-Met antibody-conjugated near-infrared fluorescent probe for in vivo imaging of hepatocellular carcinoma xenograft models

Liutong Yi1, Meilin Yang2, Nana Gong3, Meihong Yu1, Wanwei Cao1, Zhanyu Li1,†(), Dan Li2   

  1. 1. Department of Pathology, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Zhuhai 519000, China
    2. Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Zhuhai 519000, China; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Zhuhai 519000, China
    3. Department of Clinical Laboratory, the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Zhuhai 519000, China
  • Received:2021-09-18 Published:2021-11-25
  • Corresponding author: Zhanyu Li
  • About author:
    Co-first authors: Yi Liutong, Yang Meilin
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

易柳彤, 杨美林, 宫娜娜, 余美红, 曹婉维, 李展宇, 李丹. 基于c-Met抗体的近红外荧光探针用于肝癌的活体成像研究[J/OL]. 中华介入放射学电子杂志, 2021, 09(04): 407-414.

Liutong Yi, Meilin Yang, Nana Gong, Meihong Yu, Wanwei Cao, Zhanyu Li, Dan Li. c-Met antibody-conjugated near-infrared fluorescent probe for in vivo imaging of hepatocellular carcinoma xenograft models[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2021, 09(04): 407-414.

目的

探靶向近红外荧光成像为肝癌的精准诊疗带来了重要的契机，而且细胞间质表皮转化因子（c-Met）在肝癌中的表达显著高于正常肝组织。因此，本研究拟采用靶向c-Met的近红外荧光探针SHRmAb-IR800进行肝癌的活体成像研究。

方法

从TCGA和HPA数据库中获取并分析c-Met mRNA和蛋白的表达信息。通过Western Blot分析人肝癌细胞系中c-Met蛋白的表达情况。采用流式细胞技术和共聚焦成像实验评估SHRmAb-IR800与肝癌细胞的体外特异结合能力。构建肝癌皮下瘤模型，进行活体成像分析，并量化SHRmAb-IR800的成像肿瘤背景比。

结果

通过数据库分析发现肝癌中的c-Met mRNA和蛋白表达增加。Western Blot分析也显示人肝癌细胞系表达c-Met蛋白。流式细胞术和共聚焦成像实验均显示探针能特异性靶向c-Met阳性的人源肝癌细胞株；肝癌皮下瘤模型的近红外荧光成像显示靶向探针在皮下瘤的聚集显著高于对照探针（P < 0.05），并且探针在96 h的成像肿瘤背景比达到（2.01 ± 0.18）。

结论

本研究发现靶向c-Met近红外探针能够特异识别c-Met阳性的肝癌细胞和组织，有助于肝癌的诊断，在肝癌的手术导航方面具有潜在应用价值。

关键词: c-Met（细胞间质表皮转化因子）, 近红外荧光探针, 肝癌, 近红外荧光成像
Objective

Targeting near-infrared fluorescent imaging has facilitated the precise diagnosis and treatment of hepatocellular carcinoma (HCC), and cellular mesenchymal-epithelial transition factor (c-Met) has been reported as a highly expressed marker in HCC tissues compared with normal liver tissues. Thus, we intend to use the c-Met targeted near-infrared fluorescent probe SHRmAb-IR800 for imaging in HCC xenograft models.

Methods

The expression information of c-Met mRNA and protein was obtained and analyzed from TCGA and HPA databases, respectively. The expression of c-Met protein in HCC cell lines was analyzed by Western Blot. Flow cytometry and confocal imaging experiments were used to evaluate the specific binding ability of SHRmAb-IR800 with HCC cells in vitro. HCC subcutaneous xenograft models were constructed to perform in vivo imaging analysis and quantify the imaging tumor background ratio (TBR) of SHRmAb-IR800.

Results

The data extracted and analyzed from TCGA and HPA showed c-Met mRNA and protein were highly expressed in HCC tissues. Western Blot analysis also displayed that HCC cell lines expressed c-Met protein. Flow cytometry and confocal imaging were performed to verify the high specificity of SHRmAb-IR800 toward human HCC cell lines. Then the in vivo imaging of the probe in HCC xenograft models showed that the aggregation of SHRmAb-IR800 in tumor was higher than the control probe (P < 0.05). Moreover, the tumor-to-background ratio (TBR) of the probe in 96 h reached to 2.01 ± 0.18.

Conclusions

Our study demonstrated that c-Met-targeted probe had highly specific binding ability to HCC cells and tissues, which could be used to detect the HCC and have profound application potential in surgical navigation of HCC.

Key words: cellular mesenchymal-epithelial transition factor (c-Met), Near-infrared fluorescent probe, Hepatocellular carcinoma, Near-infrared fluorescent imaging
图1 数据库中c-Met的表达分析1A：在TCGA数据库中MET的表达分析；1B：MET在肝癌和正常肝组织中的表达情况；1C：蛋白数据库中c-Met的表达分析。***：P < 0.001；BLCA：膀胱尿路上皮癌；BRCA：乳腺癌浸润性癌；CESC：宫颈鳞状细胞癌；CHOL：胆管癌；COAD：结肠腺癌；ESCA：食管癌；GBM：多形性胶质母细胞瘤；HNSC：头颈部鳞状细胞癌；KICH：肾嫌色细胞癌；KIRC：肾透明细胞癌；KIRP：肾乳头状细胞癌；LIHC：肝细胞癌；LUAD：肺腺癌；LUSC：肺鳞状细胞癌；PAAD：胰腺癌；PRAD：前列腺癌；PCPG：嗜铬细胞瘤和副神经节瘤；READ：直肠腺癌；SARC：肉瘤；SKCM：皮肤黑色素瘤；THCA：甲状腺癌；THYM：胸腺瘤；STAD：胃腺癌；UCEC：子宫内膜癌。
图2 人肝癌细胞系中c-Met的表达分析2A：肝癌细胞系中c-Met的表达情况；2B：c-Met表达的量化分析。
图3 SHRmAb-IR800的体外结合能力分析3A~3B：探针与肝癌细胞孵育后的流式细胞术分析；3C：SHRmAb-IR800与SK-Hep1孵育后的共聚焦成像实验；比例尺：10 μm。
图4 SHRmAb-IR800在SK-Hep1肝癌皮下模型中的活体成像分析4A：SHRmAb-IR800在肝癌下瘤模型中的活体成像；4B：活体成像的MFI分析；*：P < 0.05。
图5 SHRmAb-IR800在SK-Hep1肝癌皮下瘤模型中的离体成像分析5A：皮下瘤和主要脏器的离体成像；5B：离体成像的定量分析；*：P < 0.05。
图6 SK-Hep1肝癌皮下瘤的c-Met免疫组化染色分析，比例尺：200 μm & 100 μm
[1]
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-1255.
[2]
Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114.
[3]
海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版)[J]. 中华肿瘤杂志, 2021, 43(4): 414-430.
[4]
Fu R, Jiang S, Li J, et al. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression[J]. Med Oncol, 2020, 37(4): 24.
[5]
Nakaseko Y, Ishizawa T, Saiura A. Fluorescence-guided surgery for liver tumors[J]. J Surg Oncol, 2018, 118(2): 324-331.
[6]
Majlesara A, Golriz M, Hafezi M, et al. Indocyanine green fluorescence imaging in hepatobiliary surgery[J]. Photodiagnosis Photodyn Ther, 2017, 17: 208-215.
[7]
Hu Z, Fang C, Li B, et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-I/II windows[J]. Nat Biomed Eng, 2020, 4(3):259-271.
[8]
Sevick-Muraca EM. Translation of near-infrared fluorescence imaging technologies: emerging clinical applications[J]. Annu Rev Med, 2012, 63: 217-231.
[9]
Lu G, van den Berg NS, Martin BA, et al. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 753-764.
[10]
Gao RW, Teraphongphom N, de Boer E, et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers[J]. Theranostics, 2018, 8(9): 2488-2495.
[11]
Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma[J]. Hepatology, 2018, 67(3): 1132-1149.
[12]
Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma[J]. Hepatology, 1997, 25(3): 619-623.
[13]
Esfahani SA, Heidari P, Kim SA, et al. Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors[J]. Theranostics, 2016, 6(12): 2028-2038.
[14]
Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer[J]. Ther Adv Med Oncol, 2011, 3(1 Suppl): S21-S35.
[15]
Bradley CA, Salto-Tellez M, Laurent-Puig P, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges[J]. Nat Rev Clin Oncol, 2017, 14(9): 562-576.
[16]
Yang C, Zhao X, Sun X, et al. Preclinical pharmacokinetics ofa novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates[J]. Xenobiotica, 2019, 49(9): 1097-1105.
[17]
Liang M, Yang M, Wang F, et al. Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model[J]. J Control Release, 2021, 332: 171-183.
[18]
Li D, Yang M, Liang M, et al. c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models[J]. Biomater Sci, 2021, 9(20): 6737-6752.
[19]
Olson MT, Ly QP, Mohs AM. Fluorescence guidance in surgical oncology: challenges, opportunities, and translation[J]. Mol Imaging Biol, 2019, 21(2): 200-218.
[20]
van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results[J]. Nat Med, 2011, 17(10): 1315-1319.
[21]
Burggraaf J, Kamerling IM, Gordon PB, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met[J]. Nat Med, 2015, 21(8): 955-961.
[22]
Zhu S, Yung BC, Chandra S, et al. Near-infrared-II (NIR-II) bioimaging via off-Peak NIR-I fluorescence emission[J]. Theranostics, 2018, 8(15): 4141-4151.
[23]
Boonstra MC, Tolner B, Schaafsma BE, et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors[J]. Int J Cancer, 2015, 137(8): 1910-1920.
[24]
Yang C, Zhao X, Sun X, et al. Preclinical pharmacokinetics ofa novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates[J]. Xenobiotica, 2019, 49(9): 1097-1105.
[25]
Yang CY, Wang L, Sun X, et al. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models[J]. Acta Pharmacol Sin, 2019, 40(7): 971-979.
[26]
Gutowski M, Framery B, Boonstra MC, et al. SGM-101: an innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery[J]. Surg Oncol, 2017, 26(2): 153-162.
[27]
Boogerd L, Hoogstins C, Schaap DP, et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study[J]. Lancet Gastroenterol Hepatol, 2018, 3(3): 181-191.
[28]
Day KE, Sweeny L, Kulbersh B, et al. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma[J]. Mol Imaging Biol, 2013, 15(6): 722-729.
[29]
Rosenthal EL, Warram JM, de Boer E, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer[J]. Clin Cancer Res, 2015, 21(16):3658-3666.
[30]
Zhu S, Tian R, Antaris AL, et al. Near-infrared-II molecular dyes for cancer imaging and surgery[J]. Adv Mater, 2019, 31(24): e1900321.
[31]
Xue Z, Zeng S, Hao J. Non-invasive through-skull brain vascular imaging and small tumor diagnosis based on NIR-II emissive lanthanide nanoprobes beyond 1 500 nm[J]. Biomaterials, 2018, 171: 153-163.
[32]
Wang H, Rao B, Lou J, et al. The function of the HGF/c-Met axis in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2020, 8: 55.
[33]
Boccaccio C, Comoglio PM. Invasive growth: a Met-driven genetic programme for cancer and stem cells[J]. Nat Rev Cancer, 2006, 6(8): 637-645.
[1] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[2] 高金红, 陈玉梅, 郭韵. 基于King互动达标理论的心理疏导在腹腔镜肝癌切除术患者的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 517-520.
[3] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[4] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[5] 马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[6] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[7] 王飞, 陈政, 余德才, 曹亚娟. 原发性肝癌合并门静脉高压症的微创手术治疗[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 306-310.
[8] 张敏, 朱建华, 缪雅芳, 郭锦荣. 菝葜皂苷元对肝癌HepG2细胞抑制作用的机制研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 328-335.
[9] 曾聿理, 雷发容, 肖慧, 邱德亮, 谢静, 吴寻. 氯普鲁卡因通过调控circRNA-ZKSCAN1表达抑制肝癌Huh-7细胞体外生长和转移的研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 220-228.
[10] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[11] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12] 鲍乐, 刘颖, 王友彬, 陈龙, 朱玉芝, 梁爽, 权鹤太, 李鹏飞. 还阳通络灸在原发性肝癌介入治疗中的临床应用研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 197-202.
[13] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[14] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[15] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号